Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Total Current Assets

All assets expected to be converted to cash or used up within one year.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets rises 132.4% from a year ago

Total current assets stood at $63.55M at the end of Q1 FY2026, up 132.4% from a year earlier and up 29.8% from the prior quarter. Over 3 fiscal years it compounded at +164.6% a year.

Context

  • Total current assets amounted to 98.7% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
  • Total current assets increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +132.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$63.55M+29.8% QoQ
Last fiscal yearDec 2025
$48.96M+58.2% YoY
Year agoMar 2025
$27.35M+132.4% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+132.4%——
1 year+58.2%——
3-year CAGR+164.6%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
48.96M USD
Year-over-year change
+58.2%
4-year CAGR
+27.7%

Total Current Assets vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +132.4% is the 3rd highest of 10, against a peer median of +27.8%.
  • Total current assets amounts to 98.7% of total assets for UNCY, versus a peer median of 96.9%.
UNCY Competitors
Total Current Assets for UNCY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RLMDRelmada Therapeutics, Inc.Mar 2026$235.34M USD+750.9%-15.0%100.0%
IMUXImmunic, Inc.Mar 2026$188.76M USD+894.8%-43.4%99.5%
VXRTVaxart, Inc.Mar 2026$131.7M USD+110.2%+11.0%73.1%
CAMPCAMP4 Therapeutics CorporationMar 2026$102.2M USD+97.8%—96.9%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$99.22M USD-34.4%-3.0%92.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$95.78M USD-41.4%-22.4%99.2%
UNCYUnicycive Therapeutics, Inc.Mar 2026$63.55M USD+132.4%+164.6%98.7%
BMEABiomea Fusion, Inc.Mar 2026$46.32M USD+3.7%-21.0%99.9%
CBUSCibus, Inc.Mar 2026$33.07M USD+27.8%+42.9%10.2%
HYFTMindWalk Holdings Corp.Jan 2026CA$18.96M CAD-8.6%-20.6%81.9%
Peer median (excluding UNCY) —+27.8%-17.8%96.9%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents16.58M455K9.7M26.14M29.2M
Short-term Investments000012.07M
Net Receivables00000
Inventory00000
Other Current Assets126K159K325K939K1.17M
Total Current Assets18.41M2.64M13.4M30.95M48.96M
Property, Plant & Equipment (Net)333K174K792K720K174K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets333K174K792K720K174K
Total Assets18.74M2.82M14.19M31.67M49.14M
Account Payables742K846K821K966K301K
Short-term Debt29K46K18K92K82K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities(29K)013.13M18.94M16.92M
Total Current Liabilities2.11M3.28M17.53M24.12M18.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities155K0466K117K0
Total Liabilities2.26M3.28M18M24.24M18.94M
Common Stock15K15K35K114K22K
Retained Earnings(15.94M)(34M)(64.54M)(101.27M)(127.83M)
Accumulated OCI0000(1K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity16.48M(466K)(3.81M)7.43M30.2M
Total Debt335K201K811K773K199K
Net Debt(16.24M)(254K)(8.89M)(25.37M)(29M)

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.